Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BMS receives additional marketing rights for cancer drug
With this expanded deal, BMS has got the right to develop and commercialize BMS-936558/ONO-4538 in the rest of the world, except in Japan, Korea and Taiwan. This agreement
With this expanded deal, BMS has got the right to develop and commercialize BMS-936558/ONO-4538 in the rest of the world, except in Japan, Korea and Taiwan. This agreement
Matrix’s Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300mg/300mg are generic equivalent to Epivir of GlaxoSmithKline, Viread of Gilead Sciences and Viramune of Boehringer Ingelheim. According to the Mylan’s
GPEx technology is used to develop mammalian cell line and create stable, high expression cell lines that will speed biologics drug development. TBI is a biologics supplier and
The agreement is also extended to include another company – Ortho-Clinical Diagnostics. As per the agreement, the three companies will partner to develop and to apply regulatory approvals
Christely has collaborated with AstraZeneca, Pfizer, Dainippon Sumitomo, multiple financing transactions as well as M&A, divestments and strategic restructurings. In 2001 he served Atugen as chief financial officer
Glucarpidase is an investigational product which is indicated for the rapid and sustained reduction of toxic methotrexate levels due to impaired renal function. Additionally, the agency has granted
The drug is being distributed by Ziwell Medical in Singapore. Following HSA’s decision, all sales and distribution of Zerin tablets have been discontinued from the public healthcare institutions,
The drugs which will be discovered will target the diseases that interest to Boehringer. As per the terms of the agreement, Nuevolution is responsible to get an upfront
The trial aims to evaluate the the safety and tolerability of intravenous ME-143 in patients with refractory solid tumors. The Phase I trial expects to recruit around 24
Under the deal, the companies will initially work on chemical compounds that target TDP-43, a protein that is a prime suspect in the disease. With their three year